Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$9.37-10.33%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SNDX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -74.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 48.3% |
Growth built into the price is above our model estimate.
The price assumes 122.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
SNDX — earnings miss
Dated 2026-11-02
and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Both Phase 2 studies have topline data due in Q4 2026. Positive results would support testing axatilimab in these new settings.
Watch forBoth studies report Q4 topline data. Each meets its main goal, with no major safety concerns reported.
Also watch forEither study misses its main goal, reports a major safety concern, or does not report data in Q4.
Why it matters: These results could show if revumenib may help another group of people with acute leukemia.
Watch forSyndax reports the Q4 data and shows tumor response in the treated NUP98 patients.
Also watch forThe data show no tumor responses, a major safety concern, or a delay beyond Q4.
Why it matters: The Phase 1/2 trial will test revumenib in myelofibrosis. Its results are also set to guide work on the newer SNDX-62122 drug.
Supportive ifSyndax starts the Phase 1/2 revumenib MF trial in Q4 2026 and later gives an enrollment update.
Worry ifThe trial has not started by the end of Q4 2026, or Syndax reports a delay.
Why it matters: The filing would move the EGFR drug closer to its first human study. Syndax named NSCLC groups with unmet needs as targets.
Supportive ifSyndax files an IND for SNDX-4321 by December 31, 2026, then starts its Phase 1 trial in 2027.
Worry ifSyndax does not file the IND by December 31, 2026, or announces a delay to the 2027 trial.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$226 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $484 loss on $10,000 · 4.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,274 loss on $10,000 · 62.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Revuforj revenue rose from $48.9 million in Q1 to $54.7 million in Q2. Another rise would show sales growth is continuing.
Supportive ifQ3 Revuforj net revenue is above $54.7 million. Prescriptions are also above about 1,500.
Worry ifQ3 Revuforj net revenue is below $54.7 million, or prescriptions fall below about 1,500.